With the goal to better support our partners in their immunoassays, our strategy is to expand and diverse our biomaterials' portfolio. Our target is to increase it by 30 new innovative markers in the next 3 years, and we are excited to share that during 2022 we have already added 15 new markers for 6 different clinical areas:

​

To provide better support for our partners, we have R&D and prototype samples ready for testing, so the performance can be assessed at the initial steps of the development. This way, we reduce risks in later stages of the project, while adapting and optimizing our new biomaterials according to our partners feedback.

Also, you can rely in our biomaterials in catalogue that have been used in several commercial immunoassays.